Celularity
Celularity Inc
Celularity Inc. is a clinical-stage biotechnology company that develops cellular and regenerative medicines. It focuses on creating 'off-the-shelf' allogeneic cell therapies derived from the unique properties of the postpartum placenta to treat cancer, immune disorders, and degenerative diseases.
Products & Team
Allogeneic Cell Therapy Platform
Celularity's primary focus is its platform for developing allogeneic, or 'off-the-shelf', cell therapies. This includes unmodified natural killer (NK) cells, genetically modified NK cells, and T-cells engineered with a Chimeric Antigen Receptor (CAR T-cells), such as the CYCART-19 candidate for hematologic cancers. All therapies are derived from postpartum placental cells, intended to provide a readily available and scalable treatment source.
The platform addresses the significant unmet medical need for effective cancer and degenerative disease treatments by providing therapies that are readily available, avoiding the logistical and cost barriers associated with autologous or matched-donor cell therapies.
For patients, the platform addresses the lack of effective or accessible therapies for difficult-to-treat diseases. For healthcare professionals, it provides advanced biomaterials to support tissue regeneration. For bio-banking clients, it offers a way to secure potential future cellular therapeutic options for their family.